{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T23:46:37Z","timestamp":1748907997049},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T00:00:00Z","timestamp":1505433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T00:00:00Z","timestamp":1505433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Takeda Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s10620-017-4743-3","type":"journal-article","created":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T09:19:43Z","timestamp":1505467183000},"page":"3059-3068","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease"],"prefix":"10.1007","volume":"62","clinical-trial-number":[{"clinical-trial-number":"nct01642602","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Benjamin D.","family":"Gold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betsy","family":"Pilmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslaw","family":"Kierku\u015b","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Claudia","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gremse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,15]]},"reference":[{"key":"4743_CR1","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/MPG.0b013e31819de871","volume":"49","author":"Y Vandenplas","year":"2009","unstructured":"Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009;49:498\u2013547.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4743_CR2","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","volume":"63","author":"HB El-Serag","year":"2014","unstructured":"El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871\u2013880.","journal-title":"Gut"},{"key":"4743_CR3","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/0016-5085(92)90764-P","volume":"102","author":"NJ Talley","year":"1992","unstructured":"Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ III. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology. 1992;102:1259\u20131268.","journal-title":"Gastroenterology"},{"key":"4743_CR4","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/S0016-5085(97)70025-8","volume":"112","author":"GR Locke III","year":"1997","unstructured":"Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448\u20131456.","journal-title":"Gastroenterology"},{"key":"4743_CR5","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0002-9343(99)00121-7","volume":"106","author":"GR Locke III","year":"1999","unstructured":"Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med. 1999;106:642\u2013649.","journal-title":"Am J Med"},{"key":"4743_CR6","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1053\/j.gastro.2004.03.077","volume":"126","author":"HB El-Serag","year":"2004","unstructured":"El-Serag HB, Petersen NJ, Carter J, et al. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology. 2004;126:1692\u20131699.","journal-title":"Gastroenterology"},{"key":"4743_CR7","doi-asserted-by":"publisher","first-page":"391631","DOI":"10.5402\/2012\/391631","volume":"2012","author":"SC Nwokediuko","year":"2012","unstructured":"Nwokediuko SC. Current trends in the management of gastroesophageal reflux disease: a review. ISRN Gastroenterol. 2012;2012:391631.","journal-title":"ISRN Gastroenterol"},{"key":"4743_CR8","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.3748\/wjg.v17.i14.1858","volume":"17","author":"M Sugimoto","year":"2011","unstructured":"Sugimoto M, Nishino M, Kodaira C, et al. Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy. World J Gastroenterol. 2011;17:1858\u20131865.","journal-title":"World J Gastroenterol"},{"key":"4743_CR9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/TCRM.S14425","volume":"6","author":"EV Guimaraes","year":"2010","unstructured":"Guimaraes EV, Guerra PV, Penna FJ. Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole. Ther Clin Risk Manag. 2010;6:531\u2013537.","journal-title":"Ther Clin Risk Manag"},{"key":"4743_CR10","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s10620-006-9095-3","volume":"51","author":"SK Gupta","year":"2006","unstructured":"Gupta SK, Hassall E, Chiu YL, Amer F, Heyman MB. Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients. Dig Dis Sci. 2006;51:858\u2013863. doi:10.1007\/s10620-006-9095-3.","journal-title":"Dig Dis Sci"},{"key":"4743_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5056\/jnm.2010.16.1.8","volume":"16","author":"T Hershcovici","year":"2010","unstructured":"Hershcovici T, Fass R. Nonerosive reflux disease (NERD)\u2014an update. J Neurogastroenterol Motil. 2010;16:8\u201321.","journal-title":"J Neurogastroenterol Motil"},{"key":"4743_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3109\/00365529509090292","volume":"211","author":"R Jones","year":"1995","unstructured":"Jones R. Gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol Suppl. 1995;211:35\u201338.","journal-title":"Scand J Gastroenterol Suppl"},{"key":"4743_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.5056\/jnm.2013.19.1.70","volume":"19","author":"GS Seo","year":"2013","unstructured":"Seo GS, Jeon BJ, Chung JS, et al. The prevalence of erosive esophagitis is not significantly increased in a healthy Korean population\u2014could it be explained? A multi-center prospective study. J Neurogastroenterol Motil. 2013;19:70\u201377.","journal-title":"J Neurogastroenterol Motil"},{"key":"4743_CR14","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1136\/gutjnl-2011-300715","volume":"61","author":"E Ness-Jensen","year":"2012","unstructured":"Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Changes in prevalence, incidence and spontaneous loss of gastro-oesophageal reflux symptoms: a prospective population-based cohort study, the HUNT study. Gut. 2012;61:1390\u20131397.","journal-title":"Gut"},{"key":"4743_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2165\/00128072-200204100-00004","volume":"4","author":"BD Gold","year":"2002","unstructured":"Gold BD, Freston JW. Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment. Paediatr Drugs. 2002;4:673\u2013685.","journal-title":"Paediatr Drugs"},{"key":"4743_CR16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1001\/archpedi.154.2.150","volume":"154","author":"SP Nelson","year":"2000","unstructured":"Nelson SP, Chen EH, Syniar GM, Christoffel KK. Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med. 2000;154:150\u2013154.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"4743_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/jgh.12330","volume":"29","author":"JH Chen","year":"2014","unstructured":"Chen JH, Wang HY, Lin HH, Wang CC, Wang LY. Prevalence and determinants of gastroesophageal reflux symptoms in adolescents. J Gastroenterol Hepatol. 2014;29:269\u2013275.","journal-title":"J Gastroenterol Hepatol"},{"key":"4743_CR18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3111\/13696990903378680","volume":"12","author":"SP Nelson","year":"2009","unstructured":"Nelson SP, Kothari S, Wu EQ, Beaulieu N, McHale JM, Dabbous OH. Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy. J Med Econ. 2009;12:348\u2013355.","journal-title":"J Med Econ"},{"key":"4743_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0095-4543(05)70339-0","volume":"23","author":"PD Siegel","year":"1996","unstructured":"Siegel PD, Katz J. Respiratory complications of gastroesophageal reflux disease. Prim Care. 1996;23:433\u2013441.","journal-title":"Prim Care"},{"key":"4743_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1442-2050.2010.01089.x","volume":"24","author":"TS Gunasekaran","year":"2011","unstructured":"Gunasekaran TS, Dahlberg M. Prevalence of gastroesophageal reflux symptoms in adolescents: is there a difference in different racial and ethnic groups? Dis Esophagus. 2011;24:18\u201324.","journal-title":"Dis Esophagus"},{"key":"4743_CR21","first-page":"1853","volume":"64","author":"AD Jung","year":"2001","unstructured":"Jung AD. Gastroesophageal reflux in infants and children. Am Fam Physician. 2001;64:1853\u20131860.","journal-title":"Am Fam Physician"},{"key":"4743_CR22","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.3109\/17477166.2010.491118","volume":"6","author":"C Koebnick","year":"2011","unstructured":"Koebnick C, Getahun D, Smith N, Porter AH, Der-Sarkissian JK, Jacobsen SJ. Extreme childhood obesity is associated with increased risk for gastroesophageal reflux disease in a large population-based study. Int J Pediatr Obes. 2011;6:e257\u2013e263.","journal-title":"Int J Pediatr Obes"},{"key":"4743_CR23","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/00005176-200209000-00018","volume":"35","author":"JP Waring","year":"2002","unstructured":"Waring JP, Feiler MJ, Hunter JG, Smith CD, Gold BD. Childhood gastroesophageal reflux symptoms in adult patients. J Pediatr Gastroenterol Nutr. 2002;35:334\u2013338.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4743_CR24","first-page":"13","volume":"6","author":"DA Gremse","year":"2004","unstructured":"Gremse DA. GERD in the pediatric patient: management considerations. MedGenMed. 2004;6:13.","journal-title":"MedGenMed"},{"key":"4743_CR25","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1572-0241.2004.30098.x","volume":"99","author":"HB El-Serag","year":"2004","unstructured":"El-Serag HB, Gilger M, Carter J, Genta RM, Rabeneck L. Childhood GERD is a risk factor for GERD in adolescents and young adults. Am J Gastroenterol. 2004;99:806\u2013812.","journal-title":"Am J Gastroenterol"},{"key":"4743_CR26","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1542\/peds.2010-2719","volume":"127","author":"RJ van der Pol","year":"2011","unstructured":"van der Pol RJ, Smits MJ, van Wijk MP, Omari TI, Tabbers MM, Benninga MA. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics. 2011;127:925\u2013935.","journal-title":"Pediatrics"},{"key":"4743_CR27","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1177\/0009922806292792","volume":"45","author":"VM Tsou","year":"2006","unstructured":"Tsou VM, Baker R, Book L, et al. Multicenter, randomized, double-blind study comparing 20 and 40\u00a0mg of pantoprazole for symptom relief in adolescents (12 to 16\u00a0years of age) with gastroesophageal reflux disease (GERD). Clin Pediatr (Phila). 2006;45:741\u2013749.","journal-title":"Clin Pediatr (Phila)"},{"key":"4743_CR28","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/MPG.0b013e318148c17c","volume":"45","author":"BD Gold","year":"2007","unstructured":"Gold BD, Gunasekaran T, Tolia V, et al. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2007;45:520\u2013529.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4743_CR29","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/MPG.0b013e3182a4e718","volume":"57","author":"I Haddad","year":"2013","unstructured":"Haddad I, Kierkus J, Tron E, et al. Efficacy and safety of rabeprazole in children (1\u201311\u00a0years) with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2013;57:798\u2013807.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4743_CR30","unstructured":"Eisai. Aciphex (rabeprazole) delayed release tablets. Full prescribing information. In: Eisai Pharmaceuticals I, ed., Tokyo; 2009."},{"key":"4743_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/adc.2010.188565","volume":"96","author":"JH Lee","year":"2011","unstructured":"Lee JH, Kim MJ, Lee JS, Choe YH. The effects of three alternative treatment strategies after 8\u00a0weeks of proton pump inhibitor therapy for GERD in children. Arch Dis Child. 2011;96:9\u201313.","journal-title":"Arch Dis Child"},{"key":"4743_CR32","unstructured":"Takeda. Dexilant (dexlansoprazole) delayed release capsules. Full prescribing information. In: Takeda Pharmaceuticals America I, ed., Deerfield, IL; 2016."},{"key":"4743_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/MPG.0b013e31822a323a","volume":"54","author":"M Kukulka","year":"2012","unstructured":"Kukulka M, Wu J, Perez MC. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD. J Pediatr Gastroenterol Nutr. 2012;54:41\u201347.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4743_CR34","unstructured":"Takeda. Safety and efficacy of dexlansoprazole delayed-release capsules in treating symptomatic non-erosive gastroesophageal reflux disease in adolescents. ClinicalTrials.gov [Internet] 2014. https:\/\/clinicaltrials.gov\/show\/NCT01642602. Accessed July 27, 2016."},{"key":"4743_CR35","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20132194.","journal-title":"JAMA"},{"key":"4743_CR36","unstructured":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline: guideline for good clinical practice. J Postgrad Med. 2001;47:45\u201350."},{"key":"4743_CR37","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/MPG.0b013e318205970e","volume":"52","author":"L Kleinman","year":"2011","unstructured":"Kleinman L, Nelson S, Kothari-Talwar S, et al. Development and psychometric evaluation of 2 age-stratified versions of the Pediatric GERD Symptom and Quality of Life Questionnaire. J Pediatr Gastroenterol Nutr. 2011;52:514\u2013522.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4743_CR38","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","volume":"101","author":"N Vakil","year":"2006","unstructured":"Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900\u20131920. (quiz 1943).","journal-title":"Am J Gastroenterol"},{"key":"4743_CR39","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/ajg.2009.129","volume":"104","author":"PM Sherman","year":"2009","unstructured":"Sherman PM, Hassall E, Fagundes-Neto U, et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol. 2009;104:1278\u20131295. (quiz 1296).","journal-title":"Am J Gastroenterol"},{"key":"4743_CR40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109\u2013117.","journal-title":"Drug Saf"},{"key":"4743_CR41","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/MEG.0b013e3282f246b2","volume":"20","author":"F Pace","year":"2008","unstructured":"Pace F, Scarlata P, Casini V, Sarzi-Puttini P, Porro GB. Validation of the reflux disease questionnaire for an Italian population of patients with gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2008;20:187\u2013190.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"4743_CR42","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1136\/bmj.314.7080.572","volume":"314","author":"JM Bland","year":"1997","unstructured":"Bland JM, Altman DG. Cronbach\u2019s alpha. BMJ. 1997;314:572.","journal-title":"BMJ"},{"key":"4743_CR43","doi-asserted-by":"crossref","unstructured":"van Pinxteren B, Sigterman KE, Bonis P, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2010:CD002095.","DOI":"10.1002\/14651858.CD002095.pub4"},{"key":"4743_CR44","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/ajg.2012.444","volume":"108","author":"PO Katz","year":"2013","unstructured":"Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308\u2013328. (quiz 329).","journal-title":"Am J Gastroenterol"},{"key":"4743_CR45","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1185\/03007990802693883","volume":"25","author":"M Vakily","year":"2009","unstructured":"Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin. 2009;25:627\u2013638.","journal-title":"Curr Med Res Opin"},{"key":"4743_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/CEG.S24063","volume":"4","author":"M Kukulka","year":"2011","unstructured":"Kukulka M, Eisenberg C, Nudurupati S. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60\u00a0mg and delayed-release esomeprazole 40 mg. Clin Exp Gastroenterol. 2011;4:213\u2013220.","journal-title":"Clin Exp Gastroenterol"},{"key":"4743_CR47","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1111\/j.1365-2036.2009.04013.x","volume":"29","author":"R Fass","year":"2009","unstructured":"Fass R, Chey WD, Zakko SF, et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2009;29:1261\u20131272.","journal-title":"Aliment Pharmacol Ther"},{"key":"4743_CR48","doi-asserted-by":"publisher","first-page":"b2481","DOI":"10.1136\/bmj.b2481","volume":"339","author":"AC Ford","year":"2009","unstructured":"Ford AC, Moayyedi P. Treatment of chronic gastro-oesophageal reflux disease. BMJ. 2009;339:b2481.","journal-title":"BMJ"},{"key":"4743_CR49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/qjmed\/90.1.75","volume":"90","author":"EM Quigley","year":"1997","unstructured":"Quigley EM. Gastro-oesophageal reflux disease-spectrum or continuum? QJM. 1997;90:75\u201378.","journal-title":"QJM"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-017-4743-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4743-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4743-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:08:19Z","timestamp":1628611699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-017-4743-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,15]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["4743"],"URL":"https:\/\/doi.org\/10.1007\/s10620-017-4743-3","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,15]]},"assertion":[{"value":"13 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Betsy Pilmer was an employee of Takeda Development Center Americas, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals America, Inc. Barbara Hunt and Maria Claudia Perez are employees of Takeda Development Center Americas, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals America, Inc. Benjamin D. Gold was a consultant for Takeda Pharmaceuticals of North America. Jaroslaw Kierku\u015b and David Gremse have no relevant disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research involved human participants and was conducted according to the principles described in the Declaration of Helsinki, International Conference on Harmonization Harmonized Tripartite Guideline for Good Clinical Practice. Patient assent and parent\/guardian consent were obtained prior to commencement of study procedures.\u00a0The study protocol was reviewed and approved by Institutional Review Boards and Independent Ethics Committees.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}